Alamar Biosciences, Inc. (ALMR) Stock Price & Analysis
Alamar Biosciences, Inc. (ALMR) closed at USD 27.42 on Thursday, October 15, 2026, up 8.08% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 25.37; the Oct 15, 2026 session ranged USD 25.11–28.35 on volume of 1,260,812 shares. Market capitalization is $1.90B, with a 52-week range of USD 18.85–39.61 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALMR.md
Key facts (ALMR)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 35.4 (range 31–45).
- Total return with dividends: 1Y +24.6% vs S&P 500 +18.1%; 5Y +24.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.19, revenue estimate $30.2M.
Analysts (ALMR)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 35.4 (low 31, high 45).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-11 | Stifel | Target raised | Buy | $28 → $32 |
| 2026-08-11 | JP Morgan | Target raised | Overweight | $32 → $35 |
Total return (dividends reinvested) (ALMR)
| 1Y (from 2026-04-17) | 5Y (from 2026-04-13) | |
|---|---|---|
| Total return | +24.6% | +24.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 84.1% | 79.1% |
| Max drawdown | -38.3% (Oct 2026→Oct 2026) | -27.5% (Sep 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 27.42 |
|---|---|
| Change | ▲ 8.08% (up) |
| Previous Close | USD 25.37 |
| Open | USD 25.14 |
| Day Range | USD 25.11 – 28.35 |
| 52-Week Range | USD 18.85 – 39.61 |
| Volume | 1,260,812 shares |
| Market Cap | $1.90B |
| Exchange | NMS |
Technical Analysis (ALMR)
Nexqual's technical model rates ALMR "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.38 (neutral) |
| vs SMA50 | Below (USD 31.1) |
| MACD | -1.52 (negative) |
Analyst Ratings (ALMR)
Wall Street analysts rate ALMR "Buy" based on 5 analysts, with a mean price target of USD 35.4 (range USD 31–45), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 35.4 |
| High Target | USD 45 |
| Low Target | USD 31 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (ALMR)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $30.19M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.32 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (ALMR)
| Total Revenue | $100.42M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +82.10% |
| Gross Margin | +58.66% |
| Operating Margin | -45.98% |
| Profit Margin | -49.45% |
| Debt / Equity | 0.16 |
| Current Ratio | 11.85 |
| Total Cash | $250.05M |
| Total Debt | $51.41M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (ALMR)
Nexqual rates Alamar Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +82% YoY (latest Q) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $250M cash vs $51M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$60M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ALMR)
| Insider Ownership | +22.24% |
|---|---|
| Institutional Ownership | +58.39% |
| Shares Outstanding | 69.39M |
| Float | 36.16M |
| Short % of Float | +6.57% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (ALMR)
Alamar Biosciences, Inc. is led by Yuling Luo (age 61), Co-Founder, Chairman & CEO, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co-Founder, Chairman & CEO | Yuling Luo (age 61) |
|---|---|
| Co-Founder, COO & Director | Shiping Chen (age 62) |
| Chief Financial Officer | Justin J. McAnear (age 49) |
| President | Timothy Ogden White (age 57) |
| Chief Technology Officer | Xiao-Jun Ma |
Major Backers & Investors (ALMR)
Notable institutional backers of Alamar Biosciences, Inc. include Sands Capital Alternatives, LLC, ARK Invest, T. Rowe Price, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sands Capital Alternatives, LLC | 6.1% |
| ARK Invest | 4.36% |
| T. Rowe Price | 3.68% |
| Samsara BioCapital, LLC | 3.57% |
| Braidwell LP | 1.56% |
| Alliancebernstein L.P. | 1.45% |
| HHLR Advisors, LTD | 1.38% |
| Millennium Management | 1.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.77% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
| TMDX | TransMedics Group, Inc. | USD 76.52 | ▼ 3.3% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt